Spero Therapeutics (SPRO)
(Real Time Quote from BATS)
$2.20 USD
-0.06 (-2.66%)
Updated Aug 5, 2025 02:22 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRO 2.20 -0.06(-2.66%)
Will SPRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRO
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
SPRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Other News for SPRO
Rare Stock Picks In June 2025 - From 26 Discerning Analysts
Spero Therapeutics Increases Stock Incentive Plan Shares
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
TD Cowen Remains a Hold on Spero Therapeutics (SPRO)
Largest borrow rate increases among liquid names